Flupirtine is an aminopyridine that functions as a centrally acting non- opioid analgesic that was originally used as an analgesic for acute and chronic pain  but in 2013 due to issues with liver toxicity, the European Medicines Agency restricted its use to acute pain, for no more than two weeks, and only for people who cannot use other painkillers.  In February 2018 EMA’s Pharmacovigilance Risk Assessment Committee has recommended that, the marketing authorisation for flupirtine be withdrawn. This recommendation was based on the finding that the restrictions introduced in 2013 have not been sufficiently followed in clinical practice, and cases of serious liver injury still occurred including liver failure. As of March 2018 the marketing authorisations of flupirtine-containing medicines are not yet withdrawn and a final decision is pending. 
The . is an attitudinal assessment, which is based on an energy/action model. This assessment differs from personality assessments as it is not intended to label a person and have them work well within that label. Instead, it measures your level of energy based on your attitude, or perception and perspective of your world. Because attitude is subjective, it can be altered. By working with a coach using the ., you can alter your attitude and perspective, make a shift in your consciousness, and increase your energy and leadership effectiveness.
Anecdotal reports concerning ibogaine's effects appeared in the early 1960s.  Its anti-addictive properties were discovered accidentally by Howard Lotsof in 1962, at the age of 19, when he and five friends—all heroin addicts—noted subjective reduction of their craving and withdrawal symptoms while taking it.  Further anecdotal observation convinced Lotsof of its potential usefulness in treating substance addictions. He contracted with a Belgian company to produce ibogaine in tablet form for clinical trials in the Netherlands, and was awarded a United States patent for the product in 1985. The first objective, placebo-controlled evidence of Ibogaine's ability to attenuate opioid withdrawal in rats was published by Dzoljic et al. in 1988.  Diminution of morphine self-administration was reported in preclinical studies by Glick et al. in 1991.  Cappendijk et al. demonstrated reduction in cocaine self-administration in rats in 1993,  and Rezvani reported reduced alcohol dependence in three strains of "alcohol preferring" rats in 1995.